516 patents
Page 4 of 26
Utility
Pyrazoloquinoline Kras Inhibitors
11 May 23
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds.
Wenyu ZHU, Xiaozhao WANG, Wenqing YAO
Filed: 30 Sep 22
Utility
Quinoline Compounds As Inhibitors of Kras
11 May 23
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds.
Qinda YE, Matthew MCCAMMANT, Rocco POLICARPO, Artem SHVARTSBART, Wenyu ZHU, Jeremy ROACH, Gia HOANG, Bin HU, Gencheng LI, Robert SUSICK, Padmaja POLAM, Fenglei ZHANG, Chao QI, Xiaozhao WANG, Wenqing YAO, Alexander Sokolsky, Haolin YIN, Le ZHAO, Peter Carlsen
Filed: 13 Oct 22
Utility
Heterocyclic Compounds As Immunomodulators
11 May 23
Liangxing Wu, Bo Shen, Meizhong Xu, Wenqing Yao
Filed: 27 Dec 22
Utility
Sustained-release Dosage Forms of Ruxolitinib
4 May 23
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
Filed: 29 Dec 22
Utility
Heterocyclylamines As PI3K Inhibitors
20 Apr 23
Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, JR., Richard B. Sparks, Brent Douty, Chunhong He
Filed: 18 Jul 22
Utility
Solid Forms of an FGFR Inhibitor and Processes for Preparing the Same
20 Apr 23
The present disclosure relates to 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, solid forms and polymorphs thereof, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
William Frietze, Zhongjiang Jia, Ming Tao, Dengjin Wang, Jiacheng Zhou, Qun Li, Timothy C. Burn, Phillip C. Liu
Filed: 12 Sep 22
Utility
Triazolopyrimidines As A2A / A2B Inhibitors
20 Apr 23
Heeoon Han, Le Zhao, Wenqing Yao, Xiaozhao Wang
Filed: 8 Dec 22
Utility
Methods of treating cancer with an FGFR inhibitor
18 Apr 23
This application relates to methods of treating cancer in a patient in need thereof, comprising administering a Fibroblast Growth Factor Receptors (FGFR) inhibitor to the patient.
Tao Ji, Krishnaswamy Yeleswaram
Filed: 6 Mar 20
Utility
Tricyclic Compounds As Inhibitors of Kras
13 Apr 23
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds.
Zhenwu Li, Zhiyong YU, Jeremy Roach, Gia Hoang, Bin HU, Gencheng Li, Rory McAtee, Ken Mukai, Rocco Policarpo, Robert Susick, Xiaozhao Wang, Wenqing Yao
Filed: 13 Jul 22
Utility
Salts of a Pim Kinase Inhibitor
13 Apr 23
The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
Zhongjiang Jia, Ganfeng Cao, Qiyan Lin, Yongchun Pan, Lei Qiao, Vaqar Sharief, Chongsheng Eric Shi, Michael Xia, Changsheng Zheng, Jiacheng Zhou, Qun Li
Filed: 7 Nov 22
Utility
Biomarkers for vitiligo
11 Apr 23
Biomarkers are provided that are associated with or predictive of a subject's responsiveness to a JAK inhibitor.
Michael D. Howell, Sherry Owens, Beth Rumberger, Huiqing Liu
Filed: 18 Mar 20
Utility
Salts of 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE and Processes Related to Preparing the Same
30 Mar 23
The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Lingkai Weng, Lei Qiao, Jiacheng Zhou, Pingli Liu, Yongchun Pan
Filed: 18 Aug 22
Utility
Heterocyclic Compounds As Immunomodulators
30 Mar 23
Neil Lajkiewicz, Liangxing Wu, Wenqing Yao
Filed: 22 Nov 22
Utility
Heterocyclic compounds as immunomodulators
28 Mar 23
Liangxing Wu, Fenglei Zhang, Song Mei, Wenqing Yao
Filed: 4 May 21
Utility
Bicyclic heterocycles as FGFR inhibitors
21 Mar 23
Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
Filed: 14 Oct 20
Utility
Heterocyclic compounds as immunomodulators
21 Mar 23
Zhenwu Li, Liangxing Wu, Wenqing Yao
Filed: 25 Sep 20
Utility
Topical treatment of vitiligo by a JAK inhibitor
14 Mar 23
The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Kathleen Butler, Jim Lee, Kang Sun, Fiona Kuo, Michael Howell
Filed: 10 Jun 20
Utility
JAK1 pathway inhibitors for the treatment of gastrointestinal disease
7 Mar 23
This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating gastrointestinal diseases or disorders such as ulcerative colitis.
Krishnaswamy Yeleswaram, Paul Smith, Gregory F. Hollis
Filed: 19 Dec 19
Utility
PD-L1/STING conjugates and methods of use
7 Mar 23
The present application relates to conjugates of STING agonists and small molecule modulators of the PD-1/PD-L1 protein/protein interaction, as well as methods of treating cancer using the conjugates.
Liangxing Wu, Zhenwu Li, Wenqing Yao
Filed: 21 Nov 19
Utility
Topical formulation for a JAK inhibitor
28 Feb 23
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Filed: 25 Mar 22